Interaction of digoxin with antihypertensive drugs via MDR1

被引:44
作者
Takara, K
Kakumoto, M
Tanigawara, Y
Funakoshi, J
Sakaeda, T
Okumura, K
机构
[1] Kobe Univ, Sch Med, Dept Hosp Pharm, Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Keio Univ, Sch Med, Dept Hosp Pharm, Shinjuku Ku, Tokyo 1608582, Japan
关键词
MDR1; P-glycoprotein; digoxin; antihypertensive drugs; drug interactions; transcellular transport;
D O I
10.1016/S0024-3205(01)01494-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The multidrug transporter MDR1 (P-glycoprotein)-mediated interaction between digoxin and 29 antihypertensive drugs of various types was examined by using the MDR1 overexpressing LLC-GA5-COL150 cells, which were established by transfecting MDR1 cDNA into porcine kidney epithelial LLC-PK1 cells. These cells construct monolayers with tight junctions, and enable the evaluation of transcellular transport. The MDR1 was highly expressed on the apical membrane (urine side). The basal-to-apical and apical-to-basal transcellular transport of [H-1]digoxin in LLC-GA5-COL150 cells was time- and temperature-dependent. The basal-to-apical transport of [H-3]digoxin was markedly increased, whereas the apical-to-basal transport was decreased in LLC-GA5-COL150 cells, compared with the host LLC-PK1 cells, suggesting that [H-3]digoxin was a substrate for MDR1. Most of the Ca2+ channel blockers used here markedly inhibited basal-to-apical transport and increased apical-to-basal transport. Exceptions were diltiazem. nifedipine and nitrendipine, which hardly showed inhibitory effects on transcellular transport of [H-3]digoxin. alpha-Blocker doxazosin and beta-blocker carvedilol also inhibited transcellular transport of [H-3]digoxin. but none of the angiotensin converting enzyme inhibitors and AT(1) angiotensin II receptor antagonists used here were active. These observations will promote understanding of the digoxin-drug interactions resulting from their actions on MDR1, and which may aid in avoiding these unexpected effects of digoxin. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1491 / 1500
页数:10
相关论文
共 19 条
[1]   INTERACTION BETWEEN DIGOXIN AND CALCIUM-ANTAGONISTS AND ANTI-ARRHYTHMIC DRUGS [J].
BELZ, GG ;
DOERING, W ;
MUNKES, R ;
MATTHEWS, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (04) :410-417
[2]  
FENSTER PE, 1984, CLIN PHARMACOL THER, V36, P70, DOI 10.1038/clpt.1984.141
[3]   The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin [J].
Greiner, B ;
Eichelbaum, M ;
Fritz, P ;
Kreichgauer, HP ;
Von Richter, O ;
Zundler, J ;
Kroemer, HK .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :147-153
[4]   DIGOXIN-QUINIDINE INTERACTION - PHARMACOKINETIC EVALUATION [J].
HAGER, WD ;
FENSTER, P ;
MAYERSOHN, M ;
PERRIER, D ;
GRAVES, P ;
MARCUS, FI ;
GOLDMAN, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (22) :1238-1241
[5]   Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) [J].
Johne, A ;
Brockmöller, J ;
Bauer, S ;
Maurer, A ;
Langheinrich, M ;
Roots, I .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (04) :338-345
[6]   Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity [J].
Jonsson, O ;
Behnam-Motlagh, P ;
Persson, M ;
Henriksson, R ;
Grankvist, K .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (11) :1801-1806
[7]   CLINICAL PHARMACOKINETIC SIGNIFICANCE OF THE RENAL TUBULAR SECRETION OF DIGOXIN [J].
KOREN, G .
CLINICAL PHARMACOKINETICS, 1987, 13 (05) :334-343
[8]  
LESSEM J, 1983, CLIN THER, V5, P595
[9]  
OKAMURA N, 1993, J PHARMACOL EXP THER, V266, P1614
[10]   DIGOXIN-DILTIAZEM INTERACTION [J].
OYAMA, Y ;
FUJII, S ;
KANDA, K ;
AKINO, E ;
KAWASAKI, H ;
NAGATA, M ;
GOTO, K .
AMERICAN JOURNAL OF CARDIOLOGY, 1984, 53 (10) :1480-1481